Health Affairs, 25, no. 5 (2006): 1309-1317 doi: 10.1377/hlthaff.25.5.1309 © 2006 by Project HOPE	New Online   House Health Reform Bill   Paying for Reform   Vetting AHIP's Report   HIV/AIDS Costs   Brief: Insurance Reform   HA Blog Top 10

This Article Abstract Full Text (HTML) Reprint (PDF) Online Technical Appendix Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Reed, S. D. Articles by Schulman, K. A. Search for Related Content PubMed PubMed Citation Articles by Reed, S. D. Articles by Schulman, K. A. Related Collections Access To Care Insurance Coverage International Issues Business Of Health Pharmaceuticals Quality Of Care Research And Technology Health Spending Consumer Issues Insurance Market Evidence-Based Medicine

How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation

View larger version (14K): [in this window] [in a new window]   EXHIBIT 1 Net Present Value In Year 1 When Varying Both The Cost And The Duration Of Phase III Clinical Trials In The "Expand Phase III" Scenario

                      What's this?